You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Humanized Monoclonal Antibodies to Treat Acinetobacter Infections
SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC Topic: NIAIDDESCRIPTION (provided by applicant): In the last decade, Acinetobacter baumannii has emerged as one of the most highly antibiotic-resistant pathogens in the United States (US) and throughout the world. These infections are increasingly prevalent and highlylethal, killing 50-60% of those infected. Worse, strains of A. baumannii that no known antibiotic will kill have now emerged, and will continue ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Immunotherapeutics to prevent HCV reinfection
SBC: Integrated Biotherapeutics, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): Up to 170 million people worldwide are chronically infected with HCV Hepatitis C virus (HCV) putting the infected individuals at significant risk for cirrhosis, liver failure and liver cancer. End- stage liver diseasecaused by HCV is the leading indication of liver transplantation (LT) in the United States. However, reinfection with HCV occurs universally and ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Preparation and Characterization of 2nd Generation HIV-1 Maturation Inhibitor Dru
SBC: DFH Pharma, Inc Topic: NIAIDDESCRIPTION (provided by applicant): Despite advances in the development of HIV drugs there remains a need for new therapies. Toxicities associated with long term use of many of the approved HIV drugs coupled with the development of resistance drives the need for new and novel antivirals. Maturation inhibitors (MIs) represent one such class of HIV therapies. HIV maturation inhibitors block virus r ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Intelligent and Automatic Image Segmentation Software for High ThroughputAnalysi
SBC: CytoInformatics LLC Topic: NIAMSDESCRIPTION (provided by applicant): It is well established that aging and many chronic diseases, such as cancer and heart failure, are associated with significant losses in skeletal muscle mass and strength in humans. There is agreement across the musclebiology community that important morphological characteristics of muscle fibers, such as fiber area, the number and position of myonuclei, cellul ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Establishing BRM Polymorphisms as Predictive Biomarkers for Lung Cancer Risk
SBC: ZENAGENE, INC. Topic: NCIDESCRIPTION (provided by applicant): While there is no doubt smoking is a direct causative factor underlying the development of lung cancer, not every smoker develops lung cancer. In fact, only 10-15% of smokers develop this disease, indicating that otherfactors make certain individuals more susceptible to cancer. A number of single nucleotide polymorphisms are known to correlate with the developm ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Targeted Polymer Micelles for Treatment of Metastatic Melanoma
SBC: INTEZYNE TECHNOLOGIES, INC. Topic: NCIDESCRIPTION (provided by applicant): According to the American Cancer Society, half of all men and one-third of all women in the United States will develop cancer in their lifetime. While chemotherapy has dramatically improved the survival rate of cancer patients, it comes at the cost of severe toxicities and in some cases poor response rates. In order to address these shortcomings, equal investme ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors
SBC: SIXONE SOLUTIONS, LLC Topic: NCIDESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Mobile App Targeting Meth Use, HIV Sex Risks and ART Adherence for Gay/Bisexual Men
SBC: COG ANALYTICS, LLC Topic: NIDADESCRIPTION (provided by applicant): Methamphetamine use among gay and bisexually identified men (GBM) and other men who have sex with men (MSM) is strongly associated with HIV infection due to the concomitant high-risk sexual behaviors that often occur while using the drug. As a result, HIV prevalence is significantly higher among MSM that report frequent use of methamphetamine and highest among ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Communication in Infants and Social Screener: The CISS
SBC: PAUL H BROOKES PUBLISHING CO., INC. Topic: NIDCDDESCRIPTION (provided by applicant): Effective early intervention depends on reliable screening of risk for communication impairments as soon as possible. Established infant communication risk factors include poor attention, gestures, social connectedness,exploratory play, and speech. Although these risk factors can be detected by 12-18 mos. and reliably predict later language and social disorders ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Development of Novel LANCL2-based Anti-diabetic Compounds
SBC: Biotherapeutics, Inc. Topic: NIDDKDESCRIPTION (provided by applicant): About 28.3 million Americans have type II diabetes (T2D) and over 40.1% of middle-aged adults have prediabetes, a condition characterized by impaired glucose tolerance and insulin resistance. Current antidiabetic medications are effective in improving insulin sensitivity, but their chronic administration has significant side effects suc as cardiovascular compli ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health